English

Insider transactions

EDGAR

Arcus Biosciences, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-15.

Open-market purchases (code P): 0 transactions, — shares
Open-market sales (code S): 35 transactions, 434,039 shares; Sum of shares × price per share: 10,472,021.3313

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 72

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
Date	Reporting owner	Code	Acquired or disposed	Shares	Price per share, as filed	Value (derived)	Shares owned after	Direct or indirect	Rule 10b5-1 box	Notes	Source
2026-08-21 Filed 2026-08-24	Azoy Alexander Officer: Chief Accounting Officer	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Common Stock	Acquired (A)	2,827	15.44	43,648.88 Derived: shares × price per share. Exact value 43648.88.	42,408	Direct (D)	Yes	F1, F2 F1 The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 Includes the unvested portion of the Reporting Person's RSU grants.	Open filing 0001771961-26-000006 Read from the filing’s XML Dispute this row
2026-08-21 Filed 2026-08-24	Azoy Alexander Officer: Chief Accounting Officer	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	2,827	30	84,810 Derived: shares × price per share. Exact value 84810.	39,581	Direct (D)	Yes	F1, F2 F1 The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 Includes the unvested portion of the Reporting Person's RSU grants.	Open filing 0001771961-26-000006 Read from the filing’s XML Dispute this row
2026-08-21 Filed 2026-08-24	Azoy Alexander Officer: Chief Accounting Officer	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Derivative security: Stock Option (right to buy) — underlying Common Stock (2,827) — exercise price 15.44	Disposed (D)	2,827	0	—	3,073	Direct (D)	Yes	F1, F3 F1 The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company.	Open filing 0001771961-26-000006 Read from the filing’s XML Dispute this row
2026-07-10 Filed 2026-07-13	Jaen Juan C. Officer: President	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	19,799	28.608	566,409.792 Derived: shares × price per share. Exact value 566409.792.	822,508	Indirect (I) By Trust	Yes	F1, F3 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.17 to $29.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.	Open filing 0001422996-26-000006 Read from the filing’s XML Dispute this row
2026-07-10 Filed 2026-07-13	Jaen Juan C. Officer: President	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	268	29.397	7,878.396 Derived: shares × price per share. Exact value 7878.396.	822,240	Indirect (I) By Trust	Yes	F1, F4 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 to $29.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.	Open filing 0001422996-26-000006 Read from the filing’s XML Dispute this row
2026-07-09 Filed 2026-07-13	Jaen Juan C. Officer: President	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	48,502	30.053	1,457,630.606 Derived: shares × price per share. Exact value 1457630.606.	842,307	Indirect (I) By Trust	Yes	F1, F2 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.	Open filing 0001422996-26-000006 Read from the filing’s XML Dispute this row
2026-06-24 Filed 2026-06-24	Jaen Juan C. Officer: President	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	6,431	29.6595	190,740.2445 Derived: shares × price per share. Exact value 190740.2445.	890,809	Indirect (I) By Trust	Yes	F1, F5 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. F5 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $29.8050, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.	Open filing 0001610717-26-000294 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-24	Jaen Juan C. Officer: President	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	14,067	27.6875	389,480.0625 Derived: shares × price per share. Exact value 389480.0625.	898,937	Indirect (I) By Trust	Yes	F1, F3 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.01 to $28.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.	Open filing 0001610717-26-000294 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-24	Jaen Juan C. Officer: President	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	1,697	28.0612	47,619.8564 Derived: shares × price per share. Exact value 47619.8564.	897,240	Indirect (I) By Trust	Yes	F1, F4 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. F4 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.0050 to $28.1550, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.	Open filing 0001610717-26-000294 Read from the filing’s XML Dispute this row
2026-06-22 Filed 2026-06-24	Jaen Juan C. Officer: President	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	9,236	27.0313	249,661.0868 Derived: shares × price per share. Exact value 249661.0868.	913,004	Indirect (I) By Trust	Yes	F1, F2 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.	Open filing 0001610717-26-000294 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12	Lacey David L. Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	5,700	0	—	76,652	Direct (D)	No	F1 F1 Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.	Open filing 0001734422-26-000005 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12	Lacey David L. Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (Right to Buy) — underlying Stock Option (Rights to Buy) (16,900) — exercise price 23.30	Acquired (A)	16,900	0	—	16,900	Direct (D)	No	F2 F2 The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.	Open filing 0001734422-26-000005 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12	Machado Patrick Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	5,700	0	—	44,300	Direct (D)	No	F1 F1 Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.	Open filing 0001311210-26-000003 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12	Machado Patrick Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (Right to Buy) — underlying Stock Option (Rights to Buy) (16,900) — exercise price 23.30	Acquired (A)	16,900	0	—	16,900	Direct (D)	No	F2 F2 The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.	Open filing 0001311210-26-000003 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12	Tang Carolyn C. Officer: General Counsel	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Common Stock	Acquired (A)	34,090	2.574	87,747.66 Derived: shares × price per share. Exact value 87747.660.	184,607	Direct (D)	No	F1, F2 F1 Includes 1,783 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan. F2 Includes the unvested portion of the Reporting Person's RSU grants.	Open filing 0001836662-26-000005 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12	Tang Carolyn C. Officer: General Counsel	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Derivative security: Stock Option (Right to Buy) — underlying Common Stock (34,090) — exercise price 2.574	Disposed (D)	34,090	2.574	87,747.66 Derived: shares × price per share. Exact value 87747.660.	0	Direct (D)	No	F3 F3 The option is fully vested and has been completely exercised.	Open filing 0001836662-26-000005 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12	PERLMAN ANDREW J Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	5,700	0	—	48,325	Direct (D)	No	F1 F1 Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.	Open filing 0001201617-26-000003 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12	PERLMAN ANDREW J Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (Right to Buy) — underlying Stock Option (Rights to Buy) (16,900) — exercise price 23.30	Acquired (A)	16,900	0	—	16,900	Direct (D)	No	F2 F2 The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.	Open filing 0001201617-26-000003 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12	FALBERG KATHRYN E Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	5,700	0	—	44,300	Direct (D)	No	F1 F1 Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.	Open filing 0001206977-26-000009 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12	FALBERG KATHRYN E Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (Right to Buy) — underlying Stock Option (Rights to Buy) (16,900) — exercise price 23.30	Acquired (A)	16,900	0	—	16,900	Direct (D)	No	F3 F3 The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.	Open filing 0001206977-26-000009 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12	Ribas Antoni Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	5,700	0	—	44,300	Direct (D)	No	F1 F1 Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.	Open filing 0001792164-26-000006 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12	Ribas Antoni Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (Right to Buy) — underlying Stock Option (Rights to Buy) (16,900) — exercise price 23.30	Acquired (A)	16,900	0	—	16,900	Direct (D)	No	F2 F2 The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.	Open filing 0001792164-26-000006 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12	Lambert Nicole Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	5,700	0	—	43,000	Direct (D)	No	F1 F1 Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.	Open filing 0001770252-26-000003 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12	Lambert Nicole Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (Right to Buy) — underlying Stock Option (Rights to Buy) (16,900) — exercise price 23.30	Acquired (A)	16,900	0	—	16,900	Direct (D)	No	F2 F2 The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.	Open filing 0001770252-26-000003 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12	KANEKO YASUNORI Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	5,700	0	—	25,700	Direct (D)	No	F1 F1 Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.	Open filing 0001277503-26-000003 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12	KANEKO YASUNORI Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (Right to Buy) — underlying Stock Option (Rights to Buy) (16,900) — exercise price 23.30	Acquired (A)	16,900	0	—	16,900	Direct (D)	No	F3 F3 The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.	Open filing 0001277503-26-000003 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-01	Azoy Alexander Officer: Chief Accounting Officer	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	2,562	25.7704	66,023.7648 Derived: shares × price per share. Exact value 66023.7648.	39,581	Direct (D)	Yes	F1, F2, F3, F4 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 Consists of 2,562 shares purchased on 5/29/2026 through the Company's Employee Stock Purchase Plan. F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.67 to $25.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F4 Includes the unvested portion of the Reporting Person's RSU grants.	Open filing 0001771961-26-000004 Read from the filing’s XML Dispute this row
2026-05-11 Filed 2026-05-12	Goeltz II Robert C. Officer: Chief Financial Officer	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	7,763	25.63	198,965.69 Derived: shares × price per share. Exact value 198965.69.	84,161	Direct (D)	Yes	F1, F2 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 Includes the unvested portion of the reporting person's RSU grants.	Open filing 0001653881-26-000005 Read from the filing’s XML Dispute this row
2026-01-23 Filed 2026-01-26	Markus Richard Officer: Chief Medical Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	24,000	0	—	89,647	Direct (D)	No	F1, F2 F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. F2 Includes the unvested portion of the Reporting Person's RSU grants.	Open filing 0002056093-26-000002 Read from the filing’s XML Dispute this row
2026-01-23 Filed 2026-01-26	Markus Richard Officer: Chief Medical Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (right to buy) — underlying Common Stock (96,000) — exercise price 22.13	Acquired (A)	96,000	0	—	96,000	Direct (D)	No	F3 F3 The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.	Open filing 0002056093-26-000002 Read from the filing’s XML Dispute this row
2026-01-23 Filed 2026-01-26	Jaen Juan C. Officer: President	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	31,000	0	—	377,012	Direct (D)	No	F1, F2 F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. F2 Includes the unvested portion of the Reporting Person's RSU grants.	Open filing 0001422996-26-000004 Read from the filing’s XML Dispute this row
2026-01-23 Filed 2026-01-26	Jaen Juan C. Officer: President	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (right to buy) — underlying Common Stock (126,000) — exercise price 22.13	Acquired (A)	126,000	0	—	126,000	Direct (D)	No	F3 F3 The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.	Open filing 0001422996-26-000004 Read from the filing’s XML Dispute this row
2026-01-23 Filed 2026-01-26	ROSEN TERRY J Director · Officer: Chief Executive Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	79,000	0	—	2,236,409	Direct (D)	No	F1, F2 F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. F2 Includes the unvested portion of the Reporting Person's RSU grants.	Open filing 0001182473-26-000005 Read from the filing’s XML Dispute this row
2026-01-23 Filed 2026-01-26	ROSEN TERRY J Director · Officer: Chief Executive Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (right to buy) — underlying Common Stock (315,000) — exercise price 22.13	Acquired (A)	315,000	0	—	315,000	Direct (D)	No	F3 F3 The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.	Open filing 0001182473-26-000005 Read from the filing’s XML Dispute this row
2026-01-23 Filed 2026-01-26	Goeltz II Robert C. Officer: Chief Financial Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	24,000	0	—	91,924	Direct (D)	No	F1, F2 F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. F2 Includes the unvested portion of the Reporting Person's RSU grants.	Open filing 0001653881-26-000002 Read from the filing’s XML Dispute this row
2026-01-23 Filed 2026-01-26	Goeltz II Robert C. Officer: Chief Financial Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (right to buy) — underlying Common Stock (96,000) — exercise price 22.13	Acquired (A)	96,000	0	—	96,000	Direct (D)	No	F3 F3 The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.	Open filing 0001653881-26-000002 Read from the filing’s XML Dispute this row
2026-01-23 Filed 2026-01-26	Azoy Alexander Officer: Chief Accounting Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	21,050	0	—	39,581	Direct (D)	No	F1, F2 F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. F2 Includes the unvested portion of the Reporting Person's RSU grants.	Open filing 0001771961-26-000002 Read from the filing’s XML Dispute this row
2026-01-23 Filed 2026-01-26	Azoy Alexander Officer: Chief Accounting Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (right to buy) — underlying Common Stock (14,050) — exercise price 22.13	Acquired (A)	14,050	0	—	14,050	Direct (D)	No	F3 F3 The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.	Open filing 0001771961-26-000002 Read from the filing’s XML Dispute this row
2026-01-23 Filed 2026-01-26	Tang Carolyn C. Officer: General Counsel	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	24,000	0	—	148,734	Direct (D)	No	F1, F2 F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. F2 Includes the unvested portion of the Reporting Person's RSU grants.	Open filing 0001836662-26-000002 Read from the filing’s XML Dispute this row
2026-01-23 Filed 2026-01-26	Tang Carolyn C. Officer: General Counsel	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (right to buy) — underlying Common Stock (96,000) — exercise price 22.13	Acquired (A)	96,000	0	—	96,000	Direct (D)	No	F3 F3 The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.	Open filing 0001836662-26-000002 Read from the filing’s XML Dispute this row
2026-01-23 Filed 2026-01-26	Jarrett Jennifer Officer: Chief Operating Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	31,000	0	—	224,024	Direct (D)	No	F1, F2 F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. F2 Includes the unvested portion of the Reporting Person's RSU grants.	Open filing 0001671311-26-000002 Read from the filing’s XML Dispute this row
2026-01-23 Filed 2026-01-26	Jarrett Jennifer Officer: Chief Operating Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (right to buy) — underlying Common Stock (126,000) — exercise price 22.13	Acquired (A)	126,000	0	—	126,000	Direct (D)	No	F3 F3 The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.	Open filing 0001671311-26-000002 Read from the filing’s XML Dispute this row
2026-01-08 Filed 2026-01-09	ROSEN TERRY J Director · Officer: Chief Executive Officer	G Bona fide gift Common Stock	Disposed (D)	35,000	0	—	2,157,409	Direct (D)	No	F1, F2 F1 Represents a charitable gift by the reporting person. F2 Includes the unvested portion of the reporting person's RSU grants.	Open filing 0001182473-26-000003 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07	Jaen Juan C. Officer: President	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	29,670	21.34	633,157.8 Derived: shares × price per share. Exact value 633157.80.	924,393	Indirect (I) By Trust	Yes	F1, F2 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025. F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.975 to $21.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.	Open filing 0001422996-26-000002 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07	Jaen Juan C. Officer: President	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	2,053	22.34	45,864.02 Derived: shares × price per share. Exact value 45864.02.	922,340	Indirect (I) By Trust	Yes	F1, F3 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025. F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.04 to $22.985, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.	Open filing 0001422996-26-000002 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07	Jaen Juan C. Officer: President	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	100	23.20	2,320 Derived: shares × price per share. Exact value 2320.00.	922,240	Indirect (I) By Trust	Yes	F1 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025.	Open filing 0001422996-26-000002 Read from the filing’s XML Dispute this row
2025-12-31 Filed 2026-01-02	Goeltz II Robert C. Officer: Chief Financial Officer	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	6,552	23.38	153,185.76 Derived: shares × price per share. Exact value 153185.76.	67,924	Direct (D)	Yes	F1 F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.	Open filing 0001610717-26-000002 Read from the filing’s XML Dispute this row
2025-12-30 Filed 2026-01-02	ROSEN TERRY J Director · Officer: Chief Executive Officer	G Bona fide gift Common Stock	Disposed (D)	2,400	0	—	2,192,409	Direct (D)	No	F1 F1 2,400 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, but retains voting and dispositive power over all of the shares transferred to each trust.	Open filing 0001610717-26-000001 Read from the filing’s XML Dispute this row
2025-12-18 Filed 2025-12-18	Azoy Alexander Officer: Chief Accounting Officer	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	4,343	22.2458	96,613.5094 Derived: shares × price per share. Exact value 96613.5094.	18,531	Direct (D)	Yes	F5, F6, F3 F5 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2025. F6 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.90 to $22.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 Includes the unvested portion of the reporting person's RSU grants.	Open filing 0001771961-25-000014 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-18	Tang Carolyn C. Officer: General Counsel	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	6,810	22.1595	150,906.195 Derived: shares × price per share. Exact value 150906.1950.	124,734	Direct (D)	Yes	F1, F5, F4 F1 Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. F5 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F4 Includes the unvested portion of the reporting person's RSU grants.	Open filing 0001836662-25-000005 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 6,203 filings read, the latest filed 2026-11-13. Prior quarter ending 2026-06-30: 9,141 filings read.

Showing 1–50 of 145

Institutional holders, largest position first, as filed
Manager	Shares or principal	Value as filed	Change from the prior quarter	Source
GILEAD SCIENCES, INC.	31,424,760 SH	811,701,551 dollars	Unchanged Prior quarter: 31,424,760	Open filing 0001123292-26-001479 Filed 2026-11-06 Dispute this row
STATE STREET CORP Partly reported under another manager	5,570,292 SH	143,880,642 dollars	Lower by 459,192 Prior quarter: 6,029,484	Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
FMR LLC Partly reported under another manager	4,436,585 SH	114,596,976 dollars	Higher by 386,828 Prior quarter: 4,049,757	Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager	2,480,755 SH	64,088,874 dollars	Higher by 32,006 Prior quarter: 2,448,749	Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Siren, L.L.C. Partly reported under another manager	2,420,430 SH	62,519,707 dollars	Unchanged Prior quarter: 2,420,430	Open filing 0002005245-26-000013 Filed 2026-11-12 Dispute this row
Fisher Asset Management, LLC Partly reported under another manager	1,918,497 SH	49,554,776 dollars	Lower by 220,899 Prior quarter: 2,139,396	Open filing 0000850529-26-000009 Filed 2026-11-06 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager	1,390,719 SH	35,921,229 dollars	Lower by 43,601 Prior quarter: 1,434,320	Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
Invesco Ltd. Partly reported under another manager	1,184,953 SH	30,607,337 dollars	Higher by 339,720 Prior quarter: 845,233	Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
Aberdeen Group plc Partly reported under another manager	1,056,679 SH	27,294,019 dollars	Higher by 405,967 Prior quarter: 650,712	Open filing 0001716774-26-000032 Filed 2026-11-10 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager	765,041 SH	19,744,908 dollars	Higher by 346,798 Prior quarter: 418,243	Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
LOOMIS SAYLES CO L P Partly reported under another manager	741,283 SH	19,147,340 dollars	Not in the prior quarter’s filings read	Open filing 0000312348-26-000039 Filed 2026-11-12 Dispute this row
UBS Group AG Partly reported under another manager	665,892 SH	17,199,990 dollars	Higher by 296,836 Prior quarter: 369,056	Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager	544,259 SH	14,058,221 dollars	Higher by 1,250 Prior quarter: 543,009	Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
Candriam S.C.A.	536,823 SH	13,916,800 dollars	Lower by 125,158 Prior quarter: 661,981	Open filing 0001537014-26-000009 Filed 2026-11-03 Dispute this row
PANAGORA ASSET MANAGEMENT INC	467,340 SH	12,071,392 dollars	Not in the prior quarter’s filings read	Open filing 0000883677-26-000011 Filed 2026-11-12 Dispute this row
FIRST TRUST ADVISORS LP	460,504 SH	11,894,818 dollars	Higher by 189,070 Prior quarter: 271,434	Open filing 0001445546-26-008622 Filed 2026-11-12 Dispute this row
PRINCIPAL FINANCIAL GROUP INC Partly reported under another manager	439,195 SH	11,344,408 dollars	Higher by 15,829 Prior quarter: 423,366	Open filing 0001126328-26-000225 Filed 2026-11-02 Dispute this row
Patient Square Capital LP	410,000 SH	10,590,300 dollars	Higher by 54,200 Prior quarter: 355,800	Open filing 0001819257-26-000007 Filed 2026-11-10 Dispute this row
Public Sector Pension Investment Board	307,471 SH	7,004,189 dollars	Higher by 9,315 Prior quarter: 298,156	Open filing 0001396318-26-000039 Filed 2026-11-10 Dispute this row
Nuveen, LLC Partly reported under another manager	233,051 SH	6,019,707 dollars	Lower by 1,001 Prior quarter: 234,052	Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
RHUMBLINE ADVISERS	232,631 SH	6,008,826 dollars	Higher by 13,450 Prior quarter: 219,181	Open filing 0001115418-26-000015 Filed 2026-11-10 Dispute this row
Ensign Peak Advisors, Inc	185,462 SH	4,790,483 dollars	Lower by 30,151 Prior quarter: 215,613	Open filing 0001454984-26-000011 Filed 2026-11-12 Dispute this row
Swiss National Bank	165,296 SH	4,269,596 dollars	Lower by 10,800 Prior quarter: 176,096	Open filing 0001582202-26-000008 Filed 2026-11-12 Dispute this row
Russell Investments Group, Ltd. Partly reported under another manager	134,530 SH	3,474,926 dollars	Higher by 52,981 Prior quarter: 81,549	Open filing 0001193125-26-451241 Filed 2026-11-06 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager	104,040 SH	2,687,353 dollars	Lower by 49,069 Prior quarter: 153,109	Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager	102,500 SH	2,647,575 dollars	Not in the prior quarter’s filings read	Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
Knott David M Jr Partly reported under another manager	100,241 SH	2,589,225 dollars	Higher by 19,000 Prior quarter: 81,241	Open filing 0001104659-26-125757 Filed 2026-11-12 Dispute this row
NEW YORK STATE TEACHERS RETIREMENT SYSTEM	92,631 SH	2,393 dollars	Higher by 200 Prior quarter: 92,431	Open filing 0000314969-26-000011 Filed 2026-10-22 Dispute this row
TEMA ETFS LLC	88,847 SH	2,294,918 dollars	Higher by 5,707 Prior quarter: 83,140	Open filing 0001829126-26-011223 Filed 2026-10-16 Dispute this row
DEUTSCHE BANK AG\ Partly reported under another manager	87,122 SH	2,250,361 dollars	Lower by 7,588 Prior quarter: 94,710	Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row
FOX RUN MANAGEMENT, L.L.C.	86,685 SH	2,239,074 dollars	Not in the prior quarter’s filings read	Open filing 0001420506-26-002585 Filed 2026-11-12 Dispute this row
Parallel Advisors, LLC	86,557 SH	2,235,767 dollars	Unchanged Prior quarter: 86,557	Open filing 0001690010-26-000007 Filed 2026-11-03 Dispute this row
BARCLAYS PLC Partly reported under another manager	85,064 SH	2,197,204 dollars	Higher by 65,746 Prior quarter: 19,318	Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
Connor, Clark Lunn Investment Management Ltd.	82,803 SH	2,138,801 dollars	Lower by 142,205 Prior quarter: 225,008	Open filing 0001596800-26-000018 Filed 2026-11-10 Dispute this row
Thrivent Financial for Lutherans	57,501 SH	1,485 dollars	Lower by 21,217 Prior quarter: 78,718	Open filing 0001193125-26-449292 Filed 2026-11-05 Dispute this row
CITIGROUP INC Partly reported under another manager	56,268 SH	1,453,402 dollars	Lower by 55,970 Prior quarter: 112,238	Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
WINTON GROUP Ltd	52,166 SH	1,347,448 dollars	Lower by 232 Prior quarter: 52,398	Open filing 0001612063-26-000014 Filed 2026-11-12 Dispute this row
VOYA INVESTMENT MANAGEMENT LLC Partly reported under another manager	51,193 SH	1,322,315 dollars	Higher by 33,992 Prior quarter: 17,201	Open filing 0001068837-26-000006 Filed 2026-11-10 Dispute this row
Illinois Municipal Retirement Fund	45,720 SH	1,180,948 dollars	Lower by 5,494 Prior quarter: 51,214	Open filing 0001541910-26-000010 Filed 2026-11-05 Dispute this row
Zurcher Kantonalbank (Zurich Cantonalbank) Partly reported under another manager	40,374 SH	1,042,860 dollars	Lower by 18,647 Prior quarter: 59,021	Open filing 0001368163-26-000007 Filed 2026-11-10 Dispute this row
Handelsbanken Fonder AB Partly reported under another manager	39,000 SH	1,007 dollars	Unchanged Prior quarter: 39,000	Open filing 0001398318-26-000012 Filed 2026-11-09 Dispute this row
Louisiana State Employees Retirement System	38,500 SH	994,455 dollars	Higher by 500 Prior quarter: 38,000	Open filing 0001537191-26-000006 Filed 2026-10-20 Dispute this row
Universal- Beteiligungs- und Servicegesellschaft mbH Partly reported under another manager	36,380 SH	939,695 dollars	Higher by 3,789 Prior quarter: 32,591	Open filing 0002057170-26-000022 Filed 2026-11-10 Dispute this row
SEI INVESTMENTS CO Partly reported under another manager	35,905 SH	927,425 dollars	Higher by 21,794 Prior quarter: 14,111	Open filing 0000350894-26-000059 Filed 2026-11-10 Dispute this row
PROFUND ADVISORS LLC	34,584 SH	893,305 dollars	Lower by 4,948 Prior quarter: 39,532	Open filing 0001129919-26-000005 Filed 2026-10-29 Dispute this row
VICTORY CAPITAL MANAGEMENT INC	33,487 SH	864,969 dollars	Higher by 19,587 Prior quarter: 13,900	Open filing 0001040188-26-000051 Filed 2026-11-10 Dispute this row
Creative Planning Partly reported under another manager	33,241 SH	858,615 dollars	Higher by 1,899 Prior quarter: 31,342	Open filing 0001540235-26-000006 Filed 2026-11-02 Dispute this row
JPMORGAN CHASE CO Option: Call Partly reported under another manager	30,000 SH	769,500 dollars	Unchanged Prior quarter: 30,000	Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
JPMORGAN CHASE CO Option: Put Partly reported under another manager	30,000 SH	769,500 dollars	Unchanged Prior quarter: 30,000	Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
Squarepoint Ops LLC Partly reported under another manager	29,877 SH	771,723 dollars	Higher by 14,726 Prior quarter: 15,151	Open filing 0001642575-26-000012 Filed 2026-11-09 Dispute this row

Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

BlackRock, Inc. 16,416,249 SH
WELLINGTON MANAGEMENT GROUP LLP 5,895,448 SH
MONTANOVA CAPITAL, LLC 4,776,423 SH
VANGUARD PORTFOLIO MANAGEMENT LLC 4,475,528 SH
VANGUARD CAPITAL MANAGEMENT LLC 3,888,346 SH
CITADEL ADVISORS LLC 3,135,057 SH
Woodline Partners LP 3,007,798 SH
MARSHALL WACE, LLP 1,945,088 SH
SAMLYN CAPITAL, LLC 1,547,182 SH
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1,419,533 SH
GOLDMAN SACHS GROUP INC 1,387,566 SH
Soleus Capital Management, L.P. 1,168,738 SH
Sofinnova Investments, Inc. 945,690 SH
Sixth Street Partners Management Company, L.P. 941,756 SH
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 941,756 SH
NORTHERN TRUST CORP 932,523 SH
Parkman Healthcare Partners LLC 919,266 SH
BAKER BROS. ADVISORS LP 844,816 SH
BANK OF AMERICA CORP /DE/ 835,504 SH
MORGAN STANLEY 795,912 SH
Logos Global Management LP 650,000 SH
TWO SIGMA INVESTMENTS, LP 635,404 SH
VANGUARD FIDUCIARY TRUST CO 616,088 SH
T. Rowe Price Investment Management, Inc. 589,546 SH
JACOBS LEVY EQUITY MANAGEMENT, INC 512,084 SH
Ikarian Capital, LLC 504,559 SH
Decheng Capital LLC 464,779 SH
DAFNA Capital Management LLC 441,829 SH
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 379,100 SH
PDT Partners, LLC 323,567 SH
DIADEMA PARTNERS LP 223,810 SH
SUSQUEHANNA INTERNATIONAL GROUP, LLP 194,000 SH
Legal General Group Plc 191,560 SH
Rock Springs Capital Management LP 180,000 SH
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 154,398 SH
BOOTHBAY FUND MANAGEMENT, LLC 154,264 SH
AMERIPRISE FINANCIAL INC 153,813 SH
PFM Health Sciences, LP 152,129 SH
Hudson Bay Capital Management LP 140,000 SH
Man Group plc 137,763 SH
PLATINUM INVESTMENT MANAGEMENT LTD 134,217 SH
MILLENNIUM MANAGEMENT LLC 133,110 SH
ALLIANCEBERNSTEIN L.P. 126,975 SH
DIADEMA PARTNERS LP 124,000 SH
Schonfeld Strategic Advisors LLC 122,574 SH
SECTORAL ASSET MANAGEMENT INC 110,870 SH
PRUDENTIAL FINANCIAL INC 110,603 SH
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 97,410 SH
D. E. Shaw Co., Inc. 96,417 SH
PRICE T ROWE ASSOCIATES INC /MD/ 89,202 SH

Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
A change is the difference between two quarter-end snapshots, not a trade.
A position reported under another manager may also appear in that manager’s filing; rows are not added together.
Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
Holder	Percent of class	Shares held	Event date	Form	Source
Gilead Sciences, Inc. Common Stock, par value $0.0001	24.7	31,424,760.00	08/05/2026 Filed 2026-08-07	SCHEDULE 13D/AAmendment 7	Open filing 0001104659-26-092737 Dispute this row
The Vanguard Group Common Stock	0	0	03/13/2026 Filed 2026-03-26	SCHEDULE 13G/AAmendment 2	Open filing 0000102909-26-000680 Dispute this row
BlackRock, Inc. Common Stock	10.4	12,736,927	12/31/2025 Filed 2026-01-08	SCHEDULE 13G/AAmendment 6	Open filing 0002012383-26-000038 Dispute this row
GILEAD SCIENCES, INC. Common Stock, par value $0.0001	25.6	31,424,760	11/03/2025 Filed 2025-11-05	SCHEDULE 13D/AAmendment 6	Open filing 0001123292-25-000613 Dispute this row
Point72 Asset Management, L.P. Common Stock, par value $0.0001 per share	4.1	4,332,479.00	09/30/2025 Filed 2025-11-14	SCHEDULE 13G/AAmendment 1	Open filing 0000902664-25-005004 Dispute this row
Point72 Capital Advisors, Inc. Common Stock, par value $0.0001 per share	4.1	4,332,479.00	09/30/2025 Filed 2025-11-14	SCHEDULE 13G/AAmendment 1	Open filing 0000902664-25-005004 Dispute this row
Steven A. Cohen Common Stock, par value $0.0001 per share	4.1	4,332,479.00	09/30/2025 Filed 2025-11-14	SCHEDULE 13G/AAmendment 1	Open filing 0000902664-25-005004 Dispute this row
GILEAD SCIENCES, INC. Common Stock, par value $0.0001	29.7	31,424,760	07/13/2025 Filed 2025-07-15	SCHEDULE 13D/AAmendment 5	Open filing 0001123292-25-000309 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

1,970,197 filings read, dated 2004-06-14 to 2026-11-13: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing year	Filings read
2015	1
2016	204,322
2017	202,494
2018	202,048
2019	193,638
2020	144,184
2021	224,474
2022	40,015
2023	199,811
2024	84,357
2025	235,520
2026	233,555

Filings made before the SEC required XML are listed, not extracted.

Back to Arcus Biosciences, Inc.